Synektik S.A.

Synektik S.A. Reports Estimated Consolidated Revenue Growth of 34% in First Half of Financial Year

Synektik S.A., a leading Polish medical technology company, has announced preliminary estimates for its consolidated revenues in the first half of the 2025 financial year, ending March 31, 2026. The company projects revenues of approximately 441 million PLN, marking a significant 34% increase compared to 327.8 million PLN in the same period the previous year.

For the January-March 2026 quarter, Synektik estimates revenues of around 213 million PLN, representing a remarkable 71% growth compared to the corresponding quarter of the 2024 financial year. The company emphasized that these figures are provisional and subject to adjustments, with final results to be disclosed on June 11, 2026, in its interim consolidated financial report.

This substantial growth underscores Synektik's strong market position in the production of radiopharmaceuticals, distribution of advanced medical equipment, and IT solutions for healthcare.

Relevance: The article highlights Synektik's robust financial performance, reflecting its leadership in key business segments such as radiopharmaceuticals and robotic surgical systems, including the da Vinci platform, which aligns with its strategic focus on innovation and market expansion.

Healthcare Access Restrictions Could Worsen Patient Wait Times, Warns Expert

Healthcare expert and former Deputy Minister of Health, Krzysztof Łanda, has raised concerns over the growing issue of patient wait times in Poland. In a recent interview, Łanda criticized the National Health Fund's (NFZ) restrictions on imaging diagnostics, such as CT and MRI scans, calling them a "desperate attempt to cut costs." He warned that these limitations could lead to record-high wait times for medical services in the coming year, further deteriorating patient care.

Łanda emphasized that systemic reforms, including changes to service tariffs, hybrid hospital financing models, and the implementation of quality-focused tools like registries, could have prevented the current crisis. He also highlighted the alarming trend of reduced access to cost-effective and highly efficient medical services, which he believes undermines public health fundamentals. According to Łanda, the Polish healthcare system is facing a "boiling frog syndrome," where the public has become desensitized to the worsening situation, accepting long wait times as the norm.

Since 2012, when the Watch Health Care Foundation began tracking data, patient queues have nearly doubled, despite increased healthcare spending. Łanda's remarks underscore the urgent need for comprehensive healthcare reforms to address these systemic issues and improve access to essential medical services.

Relevance to Synektik S.A.: As a leading provider of advanced medical technologies, including imaging systems and radioisotopes for diagnostics, Synektik S.A. is directly impacted by policies affecting access to imaging services. The company's solutions could play a critical role in addressing the challenges highlighted by Łanda, particularly in improving diagnostic efficiency and reducing patient wait times.

Advancements in Robotic Surgery Training and the Role of Technology in Poland

Poland is witnessing a significant transformation in surgical training, driven by the increasing adoption of robotic systems like the da Vinci surgical platform. Dr. Marcin Kubiak, a leading surgeon at the Wojewódzki Szpital Specjalistyczny im. Stefana kard. Wyszyńskiego in Lublin, highlights the importance of hands-on experience, specialization, and a deep understanding of operational anatomy for training robotic surgeons. He emphasizes the need to start training young surgeons directly on robotic systems, as they adapt quickly to new technologies.

Dr. Kubiak, who performed over 200 robotic surgeries in 2025, underscores the importance of large oncology centers for achieving high surgical volumes and efficient workflows. He also notes that the transition from traditional open or laparoscopic surgery to robotic surgery is seamless for experienced surgeons, as the robotic systems offer precision and control akin to open surgery but with minimally invasive benefits.

Emerging technologies like teleproctoring and artificial intelligence (AI) are set to revolutionize surgical education and practice. Teleproctoring allows real-time remote guidance during surgeries, enabling collaboration and learning across borders. Additionally, AI-powered tools are enhancing post-operative analysis, helping surgeons refine their techniques and improve patient outcomes. Dr. Kubiak also highlights the importance of dual-console robots for training residents, allowing them to gain practical experience under expert supervision.

Looking ahead, the integration of AI and robotics may lead to autonomous surgical procedures, with robots performing specific tasks under the supervision of a single surgeon. This evolution, coupled with the growing number of robotic systems in Polish hospitals, positions the country as a leader in robotic surgery training and innovation.

Relevance to Synektik S.A.: As the exclusive distributor of the da Vinci surgical system in Poland and a key player in advancing medical technologies, Synektik S.A. is directly contributing to the growth of robotic surgery and training in the country. The company's efforts in providing cutting-edge robotic systems and supporting surgeon education align with the trends and advancements highlighted in the article.

Medinice Expands into Pulsed Field Ablation and Surgical Robotics Markets

Polish medical technology company Medinice has announced plans to diversify its product portfolio by entering two high-growth segments of the global MedTech market: Pulsed Field Ablation (PFA) and surgical robotics. The company aims to develop innovative solutions in these areas, targeting advancements in minimally invasive procedures and precision medicine. This strategic move aligns with global trends in healthcare innovation, focusing on improving patient outcomes and operational efficiency in medical facilities.

Medinice's entry into the surgical robotics market positions it as a potential competitor in a field currently dominated by established players, including Synektik S.A., which is the exclusive distributor of the da Vinci surgical system in Poland. The development also highlights the growing interest in robotic-assisted surgery and advanced medical technologies in the region.

Relevance to Synektik S.A.: This development is significant for Synektik S.A. as it underscores the increasing competition in the surgical robotics market, particularly from emerging players like Medinice, which could impact Synektik's market position and growth strategy in Poland and beyond.

Synektik S.A. Secures Major Contract for da Vinci Surgical System in Slovakia

Synektik S.A., through its subsidiary SYNEKTIK Czech Republic, s.r.o., has signed a significant agreement with the University Hospital Bratislava (Univerzitná nemocnica Bratislava) in Slovakia. The contract involves the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system, along with personnel training and warranty-based service support. The deal, valued at €3,023,085.00 net, was awarded following a public procurement process under Slovak law.

The delivery and installation of the system are scheduled to be completed by May 31, 2026, with a 24-month warranty period starting from the final acceptance protocol. The agreement represents 5% of Synektik Group's equity value, as reported in its latest financial statement, and is expected to contribute to the company's revenue in FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci robotic surgical system, and reinforces its position as a leading provider of innovative healthcare solutions in Central Europe.

Synektik S.A. Reports Significant Growth in Medical Equipment Orders for FY2025

Synektik S.A., a leading Polish medical technology company, has announced a substantial increase in orders within its medical equipment, IT solutions, and services segment during the first six months of FY2025. The Group secured orders worth approximately 311 million PLN, marking a dramatic rise compared to 147 million PLN in the same period of FY2024. Notably, Q2 FY2025 orders reached 163 million PLN, a significant leap from 33 million PLN in Q2 FY2024.

As of March 31, 2026, the backlog of orders awaiting fulfillment stood at 114.3 million PLN, a sharp increase from 10.8 million PLN recorded on March 31, 2025. However, the value of active offers decreased to 165.3 million PLN from 222.4 million PLN year-over-year. The company emphasized that these figures are preliminary and subject to adjustments in its upcoming interim report.

These results underscore Synektik's growing presence in the medical technology market, aligning with its business model of providing cutting-edge medical equipment, IT solutions, and radioisotopes for diagnostic imaging.

Healthcare System Faces Leadership and Efficiency Crisis Amid Growing Pressures

The Polish healthcare system is grappling with a multifaceted crisis, including issues of financing, efficiency, and leadership, according to strategic management expert Krzysztof Zdobylak. The lack of effective leadership has hindered the resolution of systemic problems, with the National Health Fund (NFZ) criticized for implementing cost-cutting measures without adequate analysis. These measures, such as reducing reimbursement rates for certain procedures, have sparked backlash from patients, doctors, and hospitals.

Demographic, technological, and financial pressures are expected to intensify, making it imperative to adopt a dual approach: a long-term systemic transformation over three years and an immediate rescue plan focusing on efficiency. Key recommendations include improving data collection, enhancing transparency, and incentivizing healthcare providers based on performance metrics. The current system's inefficiencies, particularly in hospital financing and service delivery, highlight the need for structural reforms, including the consolidation of smaller hospitals to achieve economies of scale and improve care quality.

While Poland boasts world-class medical facilities and skilled professionals, the lack of robust quality measurement and data-driven decision-making undermines the system's overall effectiveness. The upcoming parliamentary elections are likely to delay significant reforms, as political considerations take precedence over systemic improvements.

Relevance to Synektik S.A.: The article underscores the growing importance of advanced medical technologies and data-driven solutions, areas where Synektik S.A. excels through its innovative IT platforms, diagnostic imaging systems, and robotic surgical technologies like the da Vinci system. These solutions align with the urgent need for efficiency and quality improvements in the healthcare sector.

Polish Health Minister Advocates for Optimized Healthcare Financing to Prioritize Diagnostics

Poland's Minister of Health, Jolanta Sobierańska-Grenda, has emphasized the need to restructure healthcare financing to ensure faster and more effective diagnostics for patients, particularly those with urgent needs such as oncology patients and children. In light of financial challenges faced by the National Health Fund (NFZ), the government has introduced measures such as degresive payment rates for diagnostic procedures, including CT scans, MRIs, colonoscopies, and gastroscopies, to balance costs while maintaining service availability. The minister reassured that oncology diagnostics will remain fully funded and prioritized, with 100% reimbursement for patients with DiLO cards.

Discussions are ongoing regarding further adjustments to the financing model for ambulatory specialist care, with consultations involving stakeholders and national consultants. The ministry is also exploring long-term solutions to address systemic financial shortfalls, including potential reforms to health insurance contributions. Despite record healthcare budgets, the NFZ faces a projected funding gap of 18 billion PLN by 2026, prompting the need for immediate and strategic interventions to ensure the sustainability of healthcare services.

Relevance to Synektik S.A.: The focus on improving diagnostic capabilities and prioritizing oncology patients aligns with Synektik S.A.'s expertise in advanced medical technologies, including diagnostic imaging systems and radioisotopes for PET imaging, which are critical for cancer diagnostics and treatment planning.

Poland Ordered to Fulfill COVID-19 Vaccine Contract with Pfizer, Faces Multi-Billion Zloty Penalty

The First Instance Court in Brussels has ruled that Poland must honor its agreement with American pharmaceutical giant Pfizer to purchase COVID-19 vaccines. The court ordered Poland to accept the remaining 64 million doses and pay 5.644 billion PLN, along with interest, for the unfulfilled contract. The agreement, brokered by the European Commission in 2021, obligated Poland to procure a specified number of vaccine doses. However, Poland ceased accepting deliveries in 2022, leading Pfizer to file a lawsuit in September 2023.

The court found no evidence of irregularities in the public procurement process or abuse of dominant market position by Pfizer. It also dismissed Poland's arguments that the war in Ukraine and declining infection rates justified contract termination. The ruling is not final, and Poland's Ministry of Health has announced plans to appeal, citing the need for further legal analysis regarding financial settlements and logistical aspects of vaccine delivery. A similar ruling was issued against Romania, which was ordered to pay 600 million euros for uncollected vaccines.

Relevance to Synektik S.A.: This ruling highlights the critical importance of fulfilling contractual obligations in the healthcare sector, a principle that directly impacts companies like Synektik S.A., which operates in medical technology and supplies advanced healthcare solutions under long-term agreements. Such legal precedents emphasize the need for meticulous contract management in the industry.

Poland Develops Long-Term Strategy to Boost Pharmaceutical Industry and Attract Investments

Poland is crafting a comprehensive strategy to enhance its pharmaceutical industry, focusing on fostering dialogue between the government and innovative pharmaceutical companies. According to Michał Byliniak, General Director of the Employers' Union of Innovative Pharmaceutical Companies (INFARMA), the initiative aims to align government expectations with industry needs, particularly in areas like clinical trials, investment in manufacturing facilities, and the production of active pharmaceutical ingredients (API). The strategy involves collaboration with key government bodies, including the Ministry of Health, Ministry of Finance, and Ministry of Development and Technology, to create a competitive and flexible environment for long-term investments.

Key proposals include improving the efficiency of reimbursement processes, reducing timelines for clinical trials, and removing regulatory barriers that hinder innovation. The industry also seeks government guarantees to support large-scale investments, such as building new factories and expanding production lines, which require a 15-20 year outlook. Byliniak emphasized the importance of Poland leveraging its skilled workforce, central European location, and existing capabilities in clinical research to position itself as a hub for pharmaceutical innovation. However, he noted that stronger government-industry partnerships are essential to compete with other European nations vying for similar investments.

INFARMA also highlighted the need to counter global trends, such as the U.S. "America First" policy, which has led to a reduction in the availability of new therapies in Europe. The organization stressed the urgency of creating conditions that attract cutting-edge therapies and investments to Poland, ensuring the country's pharmaceutical sector remains competitive on the global stage.

While the strategy is still in its conceptual phase, Byliniak expressed optimism about ongoing discussions with government representatives, despite challenges posed by bureaucratic silos. He called for a unified approach to address the industry's needs and secure Poland's position as a leader in pharmaceutical innovation.

Relevance to Synektik S.A.: The development of a long-term pharmaceutical strategy aligns with Synektik S.A.'s focus on innovation in medical technologies, including the production of radiopharmaceuticals and advanced diagnostic solutions, positioning the company to benefit from a more supportive and competitive industry environment in Poland.